Toggle light / dark theme

How a common fungus outsmarts drugs and our immune system

Our bodies are home to millions of fungi that, for the most part, are completely harmless. However, they can sometimes change from peaceful residents into dangerous invaders. One such is Candida parapsilosis, which normally lives on our skin or in our intestinal tract but can also be found on medical devices and hospital surfaces. If it gets into a wound or onto a catheter, it can cause a serious blood infection.

Treatments typically include a class of medicines called echinocandins, but the fungus is increasingly developing resistance to them. In a new study published in the journal Microbiology Spectrum, scientists describe how it can resist our strongest drugs and evade the immune system—by undergoing cell wall remodeling.

The researchers collected four separate samples of the fungus at different stages of a persistent blood infection. They were taken from a patient who was undergoing treatment with echinocandins but was failing to get better.

Scientists Uncover the Secret Structure Behind “Nature’s Proton Highway”

Phosphoric acid is vital in both biology and modern technology because of its exceptional ability to move electrical charge. Inside the human body and in devices such as fuel cells, this small molecule helps drive essential chemical reactions.

Scientists at the Department of Molecular Physics at the Fritz Haber Institute have now uncovered new details about how it performs this task at the molecular level.

AI Finds Life Shortening Hormone Disorder Using Only Hand Photos

A privacy-first AI can diagnose a life-shortening hormone disorder—just from a photo of your hand.

Researchers at Kobe University have developed an artificial intelligence system that can identify a rare endocrine disorder by examining photos of the back of a person’s hand and their clenched fist. By avoiding facial images, the approach was designed with privacy in mind. The team believes this tool could help doctors refer patients to specialists more efficiently and help narrow gaps in access to care.

Acromegaly and Delayed Diagnosis.

Purified diets enable experimental rigor through compositional control in animal research

Purified diets offer compositionally defined platforms that improve causal inference in nutrition studies. When aligned with the biological question, they enable targeted nutrient loss- and gain-of-function experiments, systematic lipid-source swaps, and the discovery of diet-microbiome-drug interactions. We recommend complementary validation in grain-based chow or human-relevant diets to maximize translational relevance.

Engineered immune therapy could help fight brain aging

Researchers at Stanford University engineered a modified version of the immune protein interleukin-10 (IL-10) that retains only its anti-inflammatory properties while eliminating its pro-inflammatory ones. When injected into aged mice, this modified protein stimulated the growth of new neurons and improved performance on memory and learning tasks, such as maze navigation and object recognition. The study, published in Immunity, suggests that age-related cognitive decline is linked to the accumulation of exhausted T-lymphocytes in the brain, chronic inflammation, and impaired microglial function — all of which reduce neurogenesis. The findings indicate that selectively modulating immune signaling could open new avenues for treating neurodegenerative diseases. The team plans to further investigate the protein’s mechanisms and explore ways to target specific cell types more precisely to minimize potential side effects.


A modified immune protein developed by Stanford researchers points to a novel strategy for combating age-related cognitive decline.

The Virtual Biotech: A Multi-Agent AI Framework for Therapeutic Discovery and Development

Drug discovery and development requires integrating diverse evidence across biological scales and data modalities. However, relevant data, tools, and expertise remain fragmented across teams and organizations, making integration difficult. To address these challenges, we introduce the Virtual Biotech, a coordinated team of AI agents that mirrors the structure of human therapeutic research organizations to support end-to-end computational discovery. The Virtual Biotech is led by a Chief Scientific Officer agent that receives scientific queries, delegates them to domain-specialized scientist agents, and integrates their outputs through data-driven reasoning. Scientist agents leverage complementary tools and knowledge sources spanning statistical genetics, functional genomics, pathways and interactions, chemoinformatics, disease biology, and clinical data. We showcase the Virtual Biotech across three translational applications. First, the agents autonomously annotated and analyzed outcomes from 55,984 clinical trials to identify genomic features of drug targets associated with trial success. More than 37,000 clinical-trialist agents curated structured trial outcomes and linked targets to multi-omic annotations, including cell-type-specific features derived by the agents from single-cell RNA-sequencing atlases. The agents discovered that drugs targeting cell-type-specific genes were 40% more likely to progress from Phase I to Phase II and 48% more likely to reach market (Phase IV), while exhibiting 32% lower adverse event rates. Second, the Virtual Biotech evaluated B7-H3 as a lung cancer target, integrating statistical genetics, single-cell, spatial, and clinicogenomic evidence to propose an antibody–drug conjugate strategy while identifying key liabilities and differentiation opportunities. Third, the platform analyzed a terminated ulcerative colitis trial targeting OSMR β to infer potential failure mechanisms and proposed biomarker-guided enrollment strategies to address precision-medicine gaps. Together, these results illustrate how the Virtual Biotech can enable more transparent, efficient, and comprehensive multi-scale therapeutic analyses, helping to accelerate early-stage drug discovery workflows while keeping human scientists in the loop.

The authors have declared no competing interest.